Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Microenvironment Profiling in Myelodysplastic Syndromes and Its Relationship to Clonal Hematopoiesis and Disease Progression

Antonieta Molero Yordi, Bárbara Tazón, Laura Gallur, Silvia Saumell, Tamara Jimenez, Teresa Ezponda, Maria Julia Montoro, Félix López Cadenas, Lídia Altimiras, Carla Sánchez Ruiz, Ana Alfonso, Olga Salamero, Ana Pérez, Soraya Peralta, Maria Diez-Campelo, Felipe Prosper, Francesc Bosch, David Valcarcel

Blood (2021) 138 (Supplement 1): 4650.

DOI: https://doi.org/10.1182/blood-2021-150104

Published: 2021

Journal Articles

Acute Myeloid Leukemia with Myelodisplasia-Related Changes (AML-MRC) Defined Only By Morphological Findings May Not Represent a Poor Prognosis AML

Blood (2019) 134 (Supplement_1): 2612.

DOI: https://doi.org/10.1182/blood-2019-129153

Published: 2019

Journal Articles

Graft-Versus-Host Disease (GVHD) Prophylaxis with Post-Transplant Cyclophosphamide (PTCY) Induces a More Tolerant Immune Response after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) in Patients Previously Exposed to Nivolumab

Juan C Nieto, PhD, Elisa Roldan, MD, Isabel Jiménez, MSc, Laura Fox, Júlia Carabia, PhD, Guillermo Orti, Lluis Puigdefàbregas, Laura Gallur, Gloria Iacoboni, MD, Priyanka Raheja, Ana Perez, Olga Salamero, MD, Carlos Palacio, David Valcarcel, MD, Marta Crespo, PhD, Francesc Bosch, MD, Pere Barba, MD

Blood (2018) 132 (Supplement 1): 3402.

DOI: https://doi.org/10.1182/blood-2018-99-114887

Published: 2018

Journal Articles

An IPSS-R Cutpoint of 3 Stratified Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) Patients (pts) into Two Risk Groups

Julia Montoro, Helena Pomares, Brayan Merchan, Antonieta Molero, Silvia Saumell, Esther Alonso, Mónica Fernández, Laura Gallur, Javier Grau, Olga Salamero, Adoración Blanco, Anna Varela, Elisa Roldán, Anna Sureda, Francesc Bosch, Montserrat Arnan Sangerman, David Valcarcel

Blood (2017) 130 (Supplement 1): 5306.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.5306.5306

Published: 2017

Journal Articles

The Co-Culture Of Primary CLL Cells With Bone Marrow Mesenchymal Cells, CD40 Ligand and CpG ODN Promotes The Proliferation Of Chemoresistant CLL Cells Phenotypically Comparable To Those From The Proliferative Centers

Noelia Purroy, MD, Pau Abrisqueta, MD, Eva Calpe, Cecilia Carpio, MD, Carles Palacio, MD, Laura Gallur, MD, Marta Crespo, PhD, Francesc Bosch, MD, PhD

Blood (2013) 122 (21): 4153.

DOI: https://doi.org/10.1182/blood.V122.21.4153.4153

Published: 2013

Journal Articles

YM155, a Small-Molecule Survivin Suppressant, Mainly Targets Primary CLL Cells Actively Proliferating and Overcomes Microenvironment-Mediated CLL Cell Protection

Noelia Purroy, MD, Pau Abrisqueta, MD, Eva Calpe, Cecilia Carpio, MD, Carles Palacio, MD, Laura Gallur, MD, Marta Crespo, PhD, Francesc Bosch, MD, PhD

Blood (2012) 120 (21): 3868.

DOI: https://doi.org/10.1182/blood.V120.21.3868.3868

Published: 2012

Journal Articles

Dose-Adjusted EPOCH Plus Rituximab in Untreated Patients with Poor Prognosis Large B-Cell, with Analysis of Germinal Center and Activated B-Cell Biomarkers. A Phase IV Study Conducted by the Spanish PETHEMA Group

Noelia Purroy, Juan Bergua, Laura Gallur, MD, Julio Prieto, Juan-Manuel Sancho, Luis Lopez, Jose A Garcia-Marco, Santiago Montes, Andres Lopez

Blood (2011) 118 (21): 593.

DOI: https://doi.org/10.1182/blood.V118.21.593.593

Published: 2011

Journal Articles

ZAP-70 Enhances Migration of Malignant B Cells towards Lymphoid Organs in a Burkitt Lymphoma Xenograft Model

Noelia Purroy, MD, Eva Calpe, Pau Abrisqueta, MD, Cecilia Carpio, MD, Carles Palacio, MD, Laura Gallur, MD, Josep Castellvi, MD, Marta Crespo, PhD, Francesc Bosch, MD, PhD

Blood (2011) 118 (21): 2844.

DOI: https://doi.org/10.1182/blood.V118.21.2844.2844

Published: 2011

Journal Articles

Global DNA Methylation Status of CD4+ T-Cell Population in Mielodysplastic Syndromes.

Angel Guerra-Moreno, Carlos Palacio, MD, Noemí Martínez-Morgado, Margarita Ortega, Maida Navarrete, M.D., Carmen Sánchez-Morata, M.D., Laura Gallur, MD, Javier Bueno, Teresa Vallespi, MD.PhD.

Blood (2009) 114 (22): 4424.

DOI: https://doi.org/10.1182/blood.V114.22.4424.4424

Published: 2009

Journal Articles

Influence of the FCGR3A-158 V/F and FCGR2A-131 H/R Polymorphism on the Response to Rituximab Therapy in Immune Thrombocytopenic Purpura and Autoimmune Hemolytic Anemia.

F. Javier Peñalver, Carlos Vilches, Alberto Albarez-Larran, Isidro Jarque, M.J. Rodriguez, Laura Gallur, Dolores Caballero, Javier Castaño, M.J. Fernandez, J. Rafael Cabrera

Blood (2007) 110 (11): 2097.

DOI: https://doi.org/10.1182/blood.V110.11.2097.2097

Published: 2007

Journal Articles

Re-Treatment with Rituximab Plus Chemotherapy in Patients with Aggressive Lymphoma Treated Previously with CHOP or CHOP-Like Combinations Plus Rituximab.

Andres Palacios, Mayda Navarrete, Laura Gallur, Javier Zuazu, Cristina Barrenetxea, Eva Sanchez, Andres Lopez

Blood (2006) 108 (11): 4707.

DOI: https://doi.org/10.1182/blood.V108.11.4707.4707

Published: 2006

Journal Articles

Dose Adjusted EPOCH Chemotherapy Plus Rituximab Combination (DA-R-EPOCH), an Effective Upfront Therapy for Patients with Poor-Risk Aggressive B-Cell Lymphomas. Results of a Pilot Study in a Single Center.

Andrés López, MD, Laura Gallur, MD, Andrés Palacios, MD, Mayda Navarrete, MD, Carmen Ruiz-Marcellán, MD, Josep Castellví, MD, Santiago Ramón y Cajal, MD, Antonio Juliá, MD

Blood (2005) 106 (11): 4716.

DOI: https://doi.org/10.1182/blood.V106.11.4716.4716

Published: 2005

Journal Articles

Mabthera (Rituximab) in the Treatment of 34 Adult Patients with Refractory Autoimmune Hemolytic Anemia (AIHA).

JRafael Cabrera, F. Javier Penalver, Isabel Millan, Alberto Alvarez-Larran, Jose L. Diez-Martin, Laura Gallur, Isidro Jarque, other 13 participants in the multicentric retrospective Spanish Study on use of Rituximab in refractory AIHA

Blood (2004) 104 (11): 1619.

DOI: https://doi.org/10.1182/blood.V104.11.1619.1619

Published: 2004

NARROW

Microenvironment Profiling in Myelodysplastic Syndromes and Its Relationship to Clonal Hematopoiesis and Disease Progression

Acute Myeloid Leukemia with Myelodisplasia-Related Changes (AML-MRC) Defined Only By Morphological Findings May Not Represent a Poor Prognosis AML

Graft-Versus-Host Disease (GVHD) Prophylaxis with Post-Transplant Cyclophosphamide (PTCY) Induces a More Tolerant Immune Response after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) in Patients Previously Exposed to Nivolumab

An IPSS-R Cutpoint of 3 Stratified Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) Patients (pts) into Two Risk Groups

The Co-Culture Of Primary CLL Cells With Bone Marrow Mesenchymal Cells, CD40 Ligand and CpG ODN Promotes The Proliferation Of Chemoresistant CLL Cells Phenotypically Comparable To Those From The Proliferative Centers

YM155, a Small-Molecule Survivin Suppressant, Mainly Targets Primary CLL Cells Actively Proliferating and Overcomes Microenvironment-Mediated CLL Cell Protection

Dose-Adjusted EPOCH Plus Rituximab in Untreated Patients with Poor Prognosis Large B-Cell, with Analysis of Germinal Center and Activated B-Cell Biomarkers. A Phase IV Study Conducted by the Spanish PETHEMA Group

ZAP-70 Enhances Migration of Malignant B Cells towards Lymphoid Organs in a Burkitt Lymphoma Xenograft Model

Global DNA Methylation Status of CD4+ T-Cell Population in Mielodysplastic Syndromes.

Influence of the FCGR3A-158 V/F and FCGR2A-131 H/R Polymorphism on the Response to Rituximab Therapy in Immune Thrombocytopenic Purpura and Autoimmune Hemolytic Anemia.

Re-Treatment with Rituximab Plus Chemotherapy in Patients with Aggressive Lymphoma Treated Previously with CHOP or CHOP-Like Combinations Plus Rituximab.

Dose Adjusted EPOCH Chemotherapy Plus Rituximab Combination (DA-R-EPOCH), an Effective Upfront Therapy for Patients with Poor-Risk Aggressive B-Cell Lymphomas. Results of a Pilot Study in a Single Center.

Mabthera (Rituximab) in the Treatment of 34 Adult Patients with Refractory Autoimmune Hemolytic Anemia (AIHA).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only